3. Further characteristics of included studies: types of CVD and status of diabetes mellitus amongst participants.
| Included studies | Acronyms of trial | ASCVD | HF | DM |
| Arturi 2017 | ‐ | 1 | 1 | 1 |
| Bhatt 2021 | SOLOIST‐WHF | 0 | 1 | 1 |
| Cannon 2020 | VERTIS CV | 1 | 0 | 1 |
| Cefalu 2015 | ‐ | 1 | ‐ | 1 |
| Gants 2017 | ‐ | 1 | 0 | 1 |
| Green 2015 | TECOS | 0 | 0 | 1 |
| Hernandez 2018 | Harmony Outcomes | 1 | 0 | 1 |
| Holman 2017 | EXSCEL | 0 | 0 | 1 |
| Husain 2019 | PIONEER 6 | 0 | 0 | 1 |
| Jorsal 2017 | LIVE | 0 | 1 | 0 |
| Kato 2017 | TOP‐SCORE | 1 | ‐ | 1 |
| Leiter 2014 | ‐ | 1 | 0 | 1 |
| Margulies 2016 | FIGHT | 0 | 1 | 0 |
| Marso 2016a | LEADER | 0 | 0 | 1 |
| Marso 2016b | SUSTAIN 6 | 0 | 0 | 1 |
| McMurray 2018 | VIVIDD | 0 | 1 | 1 |
| McMurray 2019 | DAPA‐HF | 0 | 1 | 0 |
| Neal 2017a | CANVAS (CANVAS program) | 0 | 0 | 1 |
| Neal 2017b | CANVAS‐R (CANVAS program) | 0 | 0 | 1 |
| Packer 2020 | EMPEROR‐Reduced | 0 | 1 | 0 |
| Pfeffer 2015 | ELIXA | 1 | 0 | 1 |
| Phrommintikul 2019 | ‐ | 1 | 0 | 1 |
| Rosenstock 2019 | CARMELINA | 0 | 0 | 1 |
| Scirica 2013 | SAVOR‐TIMI 53 | 0 | 0 | 1 |
| Shimizu 2020 | EMBODY | 1 | ‐ | 1 |
| Tanaka 2019 | EMBLEM | 1 | 0 | 1 |
| Tanaka 2020 | CANDLE | 0 | 1 | 1 |
| Verma 2019 | EMPA‐HEART CardioLink‐6 | 1 | 0 | 1 |
| Wang 2020 | ‐ | 1 | ‐ | 1 |
| White 2013 | EXAMINE | 1 | 0 | 1 |
| Zinman 2015 | EMPA‐REG outcome | 1 | 0 | 1 |
[1]: All the study participants had comorbidities at baseline.
[0]: Some of the study participants had comorbidities at baseline.
[‐]: data not available.
ASCVD: atherosclerotic cardiovascular disease, CVD: cardiovascular disease, DM: diabetes mellitus, HF: heart failure